Paternoster D M, Cester M, Memmo A, Scandellari R, Fabris F, Girolami A
Department of Gynaecological Sciences and Human Reproduction, University of Padova, Padova, Italy.
J Matern Fetal Neonatal Med. 2006 Aug;19(8):517-20. doi: 10.1080/14767050600746563.
We report herein three cases of severe fetal thrombocytopenia due to anti-human platelet antigen (HPA)- 1a maternal antibodies. The first and the third cases were diagnosed on the basis of previously affected siblings and treated successfully by maternal intravenous human immunoglobulins and corticosteroids. In the second case an unexpected neonatal thrombocytopenia was found after birth without previously affected siblings and treated subsequently with intravenous immunoglobulins. Our experience supports a switch from an invasive management, including early FBS (fetal blood sampling) and platelet transfusions, to a more cautious approach. Also in severe HPA-1a alloimmunization and in 'high risk' fetuses, prenatal maternal treatment could be performed, without previous FBS, only on the basis of a risk score defined by sibling history and parents' genotypes.
我们在此报告三例因抗人血小板抗原(HPA)-1a 母体抗体导致的严重胎儿血小板减少症病例。第一例和第三例是根据之前患病的兄弟姐妹确诊的,并通过母体静脉注射人免疫球蛋白和皮质类固醇成功治疗。第二例在出生后发现意外的新生儿血小板减少症,之前没有患病的兄弟姐妹,随后用静脉注射免疫球蛋白进行治疗。我们的经验支持从包括早期胎儿血样采集(FBS)和血小板输血在内的侵入性管理转向更谨慎的方法。同样,在严重的 HPA-1a 同种免疫和“高危”胎儿中,产前母体治疗可以在没有先前 FBS 的情况下,仅根据由兄弟姐妹病史和父母基因型定义的风险评分进行。